Answers are grounded in this paper and cite their sources.
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) can reduce oedema, improve vision and prevent further visual loss. These drugs have replaced laser photocoagulation as the standard of care for people with DMO.
No takes yet. Share an insight, caveat, or question.
Virgili et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: